HBM rises from the ashes as a research partner for drug giants
The cash-strapped company disposed of a factory and an advanced drug pipeline to stay in business, and is now re-positioning itself as a supplier of biomedical services Key Takeaways: HBM…
Recent Articles
RELATED ARTICLES
-
HBM gets health boost from drug licensing deals
2142.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
-
Everest reaches new heights on growing drug sales
1952.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
